Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
DDX10
REST API REST API
Homo sapiens
DDX10 is differentially expressed in 260 experiments: 97 organism parts: kidney, lung, ... (95 more);, 179 disease states: normal, control, ... (177 more);, 76 cell types 357 cell lines 45 compound treatments and 60 other conditions.
Synonyms HRH-J8
Orthologs ddx10 (Danio rerio)   Ddx10 (Rattus norvegicus)   HCA4 (Saccharomyces cerevisiae)   F1P0I3_CHICK (Gallus gallus)   Q08DT0_BOVIN (Bos taurus)   Ddx10 (Mus musculus)   CG5800 (Drosophila melanogaster)   ddx10 (Xenopus laevis)   DDX10 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term ATP-dependent helicase activity, nucleic acid binding, ATP binding, RNA helicase activity, nucleotide binding, hydrolase activity, RNA binding, helicase activity
InterPro Term DNA/RNA_helicase_DEAD/DEAH_N, RNA_helicase_DEAD_Q_motif, Helicase_C, DEAD-like_helicase
UniProt Accession Q13206, Q59EC7, E7EUR6, E9PIF2
Search EB-eye ENSG00000178105
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-803, E-GEOD-6573, E-MEXP-1251, E-MTAB-24, ... (19 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (39 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
T84
2
E-GEOD-1474, E-MTAB-37
MCF-7
2
E-GEOD-20081, E-GEOD-5823
SW480
2
E-GEOD-18005, E-MEXP-1014
U87
2
E-GEOD-20089, E-MEXP-903
gm00038c, fibroblast cell line
1
E-MTAB-62
351 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-13909, E-GEOD-20677, E-GEOD-13987, ... (36 experiments)

Factor Value U/D Experiments
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
stromal cell
1
2
E-MEXP-2034, E-GEOD-1460, E-GEOD-10797
naive B cell
1
E-TABM-702
adult native RPE from 89 y.o. donor
1
E-GEOD-18811
memory B cell
1
E-TABM-702
hematopoietic
1
E-GEOD-9894
70 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-16363, E-MTAB-62, E-GEOD-5418, ... (49 experiments)

Factor Value U/D Experiments
control
1
3
E-GEOD-21912, E-GEOD-8121, E-GEOD-20295, E-GEOD-20602
chronic myelogenous leukemia
2
E-GEOD-5550, E-MTAB-62
lung adenocarcinoma
2
E-MTAB-62, E-GEOD-2514
breast carcinoma
1
2
E-MTAB-37, E-GEOD-5823, E-MEXP-882
glioblastoma
1
2
E-GEOD-6014, E-GEOD-4290, E-MTAB-62
cervical carcinoma
1
2
E-MTAB-62, E-MTAB-37, E-GEOD-5823
173 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-1417, E-TABM-782, E-GEOD-3720, ... (29 experiments)

Factor Value U/D Experiments
none
5
7
E-MEXP-1601, E-TABM-782, E-GEOD-5824, E-GEOD-6907, E-TABM-868, ... (12 experiments)
lipopolysaccharide
2
E-GEOD-3720, E-TABM-868
control
1
2
E-GEOD-4006, E-GEOD-3284, E-GEOD-995
endotoxin
1
E-GEOD-3026
bis [(+)-tartrato] diantimonate (III) dipotassium trihydrate
1
E-GEOD-6907
keratinocyte growth factor
1
E-GEOD-7216
39 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

cd34
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-2171, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-2191, E-GEOD-21374, ... (9 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MEXP-2283, E-MTAB-62 ... (5 experiments)

Disease staging
studied in E-GEOD-19743, E-MEXP-2280, E-TABM-147, E-GEOD-3013

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-MTAB-108, E-GEOD-361, ... (7 experiments)

Genotype
studied in E-TABM-763, E-GEOD-1923, E-TABM-1029, E-GEOD-22056, E-MEXP-149, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-TABM-127, E-GEOD-20540, E-MEXP-1446, E-GEOD-22278, ... (6 experiments)

Individual
studied in E-MTAB-197, E-GEOD-2466, E-GEOD-1926, E-MEXP-2069, E-GEOD-16363, ... (25 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12254, E-MEXP-561, E-GEOD-17400 ... (5 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-1309, E-GEOD-21750, E-GEOD-17636

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

Replicate
studied in E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-19246, E-GEOD-15799, E-GEOD-12198 ... (5 experiments)

Treatments comments 99 146
studied in E-GEOD-20194, E-GEOD-16716

Processing time: 0.375 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM